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Summary 
 
The use of antipsychotics to manage challenging behaviour in adults with intellectual disability is 
widespread but controversial and lacking in evidence. There is a perception that antipsychotics used 
in this context can be reduced or discontinued and this has been a major focus of recent national 
policy. However, such an intervention risks harm as well as having potential benefits. We reviewed 
the available evidence and found that antipsychotics can be reduced or discontinued in a significant 
proportion of adults who use them for challenging behaviour, though not always without adverse 
reactions. There is a group who display behavioural deterioration on antipsychotic reduction that 
prevents discontinuation; predictors of poor response could not be reliably identified. Given the 
relative lack of data and methodological limitations of the available studies, we cannot draw firm 
conclusions to inform a population level approach to this issue. Antipsychotic medication used for 
behaviour should be reviewed regularly and an individualised approach taken to treatment.  
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Introduction 
 
Intellectual disability (ID) is a lifelong condition of impaired cognitive function and deficit in 
adaptive skills.1 Antipsychotic medication is often prescribed to adults with ID to manage 
challenging behaviour in the absence of severe mental illness.2,3 Challenging behaviour is a 
non-specific term used to describe any behaviour that may threaten the physical safety of a 
person with ID or those around them, or that is likely to limit access to ordinary community 
facilities.4 It includes presentations such as aggression, self-injury, and property destruction. 
The prevalence of challenging behaviour in those with ID is typically quoted as 10-15%,5,6 
although that this might be an underestimate.2,7 Interventions aimed at reducing the 
frequency or degree of challenging behaviour must recognise the array of biological, 
psychological, and social factors that can underlie the development and maintenance of 
behaviour disturbance.8 There is very limited evidence that antipsychotics are effective in 
reducing challenging behaviour in adults with ID.9,10 The NICE guideline on behaviour that 
challenges recommends a stepped approach to assessment and a central role for psychosocial 
strategies in management, with  antipsychotic medication being used only in certain 
circumstances and continued only when benefit is clearly demonstrated (panel 1).11  
 
There has been longstanding criticism of the use, and perceived over-use of antipsychotic 
medication in people with ID.12,13 Professionals and care providers are under close scrutiny 
following the exposure of systemic abuse of people with ID and complex challenging 
behaviours at Winterbourne View Hospital, and the prescription of psychotropic medication 
to people with ID has achieved widespread coverage in the lay and specialist media.14,15 
Transforming Care, the UK Government response to the scandal at Winterbourne View, 
restated concerns about the inappropriate use of psychotropic medication in this group.16 
These concerns were substantiated by two studies of psychotropic prescribing to people with 
ID in UK primary care.2,17 NHS England have issued a ‘Call to Action,’ 
(https://www.england.nhs.uk/2015/07/urgent-pledge/), a national drive to reduce 
antipsychotic prescription rates in people with ID.  
 
Challenging behaviour often persists and those who are prescribed antipsychotic medication 
tend to remain on it for long periods.18,19 Reasons might include; favourable drug response; 
lack of efficacy or availability of alternative (psychosocial) treatments; infrequent or 
ineffectual medication review; and lack of professional or caregiver confidence in making 
medication changes for fear of the consequence. 
 
Long-term antipsychotic use is not without risks and adverse effects associated with 
antipsychotic drugs include movement (extra-pyramidal) side-effects, autonomic 
disturbance, and endocrine and metabolic disorders.20 Some can cause sedation and those 
with a high-degree of anti-cholinergic activity might impair cognition, especially when used in 
combination with other anti-cholinergic agents.21,22 People with ID are often considered at 
greater risk of developing such side-effects23 although there has been relatively little research 
on the side-effect profile of psychotropic drugs specifically in people with ID and few studies 
directly compare side-effect rates in people with and without ID.  
 
It is desirable to reduce antipsychotic medication where possible.  There is evidence of the 
effect of antipsychotic discontinuation in adults with average intelligence who take 
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antipsychotics for severe mental illness24,25  and older adults prescribed antipsychotics for 
neuropsychiatric symptoms in dementia.26,27 Antipsychotic discontinuation in children with 
autism spectrum disorders who take antipsychotics for behaviour disorder has also been 
studied, although primarily with the intention of testing the efficacy of long-term 
antipsychotic use rather than investigating the consequences of planned reduction.28-30 As yet 
there has been no thorough review of the effect of antipsychotic discontinuation in those 
with ID and the focus of existing discontinuation studies, the participants included, and 
outcomes measured mean that results might not generalize to those with ID who take 
antipsychotics. 
 
We conducted a systematic review of the evidence concerning the outcome of reduction or 
discontinuation of long-term antipsychotic medication used for management of challenging 
behaviour in adults with ID. 
 
[Panel 1 near here] 
Methods 
 
Electronic databases (Medline, EMBASE, PsycINFO, Cochrane, CINAHL Plus) were searched for 
relevant articles published in any language between 1st January 1990 and 1st March 2016. 
Search terms for ‘intellectual disability’, ‘antipsychotic medication’ and 
‘reduction/discontinuation’ and their synonyms were combined, with relevant MeSH terms 
also included (appendix A). Reference lists of included studies were checked and their 
citations were tracked using the Science Citation Index Expanded to supplement the original 
search. The review protocol was registered with PROSPERO (2015:CRD42015019917).  
 
We included studies published in peer-reviewed journals and all study designs, including 
individual case studies, but excluded non-peer reviewed articles including letters, meeting 
abstracts, and dissertations.  
 
Adults (>18 years) with any degree of ID of any aetiology were included. ID was author-
defined and expected to conform to ICD/DSM criteria. Participants could have any physical or 
psychiatric co-morbidity, although those studies where a significant number had psychotic 
disorders were excluded. Studies conducted in community or institutional settings were 
included.  
 
Participants must have been taking an antipsychotic regularly for at least 12 weeks before the 
intervention. Studies reporting reduction or discontinuation of either first- and second-
generation antipsychotics were included. The antipsychotic must have been used primarily to 
manage challenging behaviour, rather than to treat mental illness. Challenging behaviour was 
author-defined.  
 
The reduction or discontinuation of antipsychotic medication must have been the main 
intervention. Reduction was defined as a sustained change in antipsychotic to a lower dose 
and discontinuation as the complete cessation of antipsychotic medication. Any schedule of 
reduction or discontinuation was permitted. Simultaneous interventions, including 
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adjustment of other classes of medication and psychotherapeutic interventions, were 
acceptable but studies that report the substitution of one antipsychotic for another were not 
included.  
 
The primary outcome was the proportion of participants achieving dose reduction or 
discontinuation without drop-out or reinstatement of the antipsychotic. Studies that report 
average dose changes or where change in antipsychotic use could not be differentiated from 
change in other psychotropic drugs were excluded.   
 
Secondary outcomes measures included change in behaviour, physical health, mental health, 
cognitive or adaptive functioning, and quality of life in those who reduced or discontinued 
antipsychotic medication.  
 
All citations were imported into an EndNote library. Duplicates were removed in a two-stage 
process using the software function and then manually by checking titles. The titles of the 
remaining citations were screened against the inclusion criteria. Abstracts of the remaining 
citations were reviewed allowing the exclusion of further studies. When the abstract 
indicated the paper potentially met inclusion criteria, the full text was reviewed.  
 
Included studies were categorised according to the hierarchy published by the Centre for 
Evidence-Based Medicine.31 A separate evaluation of the quality of each study was made 
focusing on limitations and biases. 
Results 
 
Study characteristics 
 
The initial search yielded a total of 1,018 citations and of these twenty-one studies met 
inclusion criteria (figure 1). Included studies are summarised in table 1. Studies excluded after 
full-text review are listed in appendix B.  
 
[Figure 1 near here] 
 
We found one (open) RCT, the results of which are reported in two papers;32,33 one case-
series34; one single-case report.35 The remainder of studies were observational studies, some 
of which included control groups.36-39 
 
Fifteen studies were conducted in the USA. Five European studies were included and one from 
Australasia. Thirteen studies included only participants living in institutions, two studies 
included only those living in community settings, five studies report on participants living in a 
range of settings, and in one study the living arrangements of participants are not reported.  
 
Studies reported the outcome of antipsychotic discontinuation or reduction in 1,027 
participants in total. Discontinuation practices included dose-reduction programmes and that 
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were under clinician control. In five studies reduction/discontinuation of antipsychotics was 
according to formal research protocol.  
 
Details of participants are incompletely reported in several studies.  Mean age of participants 
in studies ranged from 24 to 50 years, with the one case report describing outcome of 
antipsychotic discontinuation in a 74 year old. There was a predominance of men 
(approximately 2/3 of those undergoing antipsychotic reduction and discontinuation) and just 
over 80% had severe-profound ID. Participants were prescribed antipsychotics for challenging 
behaviour; in almost all cases the nature of the challenging behaviour was not given. A 
minority in each study had diagnosed co-morbid mental illness. In studies where indication 
for antipsychotic prescription was not clearly given, the authors clearly allude to challenging 
behaviour. Most of the antipsychotics were first generation agents.  
 
Outcomes of reduction or discontinuation of antipsychotic medication used for 
behaviour 
Success of attempts to reduce or discontinue antipsychotic medication  
 
Ten studies describe the outcome of reduction or discontinuation of antipsychotic medication 
as the proportion of the intervention group who were maintained on a lower dose or achieved 
drug discontinuation at follow-up (ranging from 3 months to over 10 years).32,38,40-47 The 
proportion of participants maintained on a reduced dose was between 19% and 83%, 
discontinuation of antipsychotics ranged from 4% to 74%, the proportion unsuccessful in 
attempts to reduce or discontinue antipsychotics was between 0% and 96% (table 2). In 
several cases, reporting of the study is such that it is not possible to distinguish three groups 
accurately. Due to the study designs we are unable to obtain a summary measure of the 
successful reduction or discontinuation of antipsychotics, but taken together, these studies 
have value in providing broad estimates of rates of reduction or discontinuation that might 
be achieved in a clinical setting.  
 
[Table 2 near here] 
Effect of reduction or discontinuation of antipsychotics on behaviour 
 
Six studies report the effect of antipsychotic reduction or discontinuation on participant 
behaviour.32,39,43,44,47,48 Behavioural outcome measures ranged from validated instruments to 
colloquial reports (Appendix C).  
 
[Table 3 near here] 
 
Ahmed and colleagues found no difference in challenging behaviour in the group who 
discontinued or reduced antipsychotic medication by ≥50% and the control group who 
underwent no medication change (p>0·05, data not given).32 They also report behaviour 
outcomes of the ‘failure’ group, that is, those who were randomised to the drug reduction 
arm but who did not discontinue or significantly reduce dose. This group did not demonstrate 
worsening of overall behaviour and the decision to arrest dose reduction or reinstate 
medication was found to be related to setting rather than individual variables, including 
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having fewer full-time and senior staff, lower levels of staff training, and more restrictive 
environmental features.   
 
deKuijper examined baseline and follow-up differences (12 weeks after planned 
discontinuation) in carer rated total Aberrant Behaviour Checklist (ABC) score in their 
cohort.47 In the group that completed antipsychotic discontinuation, the mean total ABC score 
reduced from 47 (sd 27) to 37 (sd 29) (p=0·03). Carer ratings of target behaviour on the Visual 
Analogue Scale (VAS) did not change (mean 6·4 (sd 1·4) vs 6·5 (sd 1·4), p=0·76). The subgroup 
who reduced antipsychotic dose but did not progress to full discontinuation also showed a 
statistically significant decline in mean ABC score from baseline to follow-up (62 (sd 27) vs 50 
(sd 36), p=0·03), although with a simultaneous increase in severity of challenging behaviour 
measured by the VAS (6·4 (sd 1·4) vs 5·8 (sd 1·6), p=0·03). Thus, the findings of the VAS 
potentially contradict the improvement in behaviour measured by the ABC. The authors 
suggest bias in the VAS scores introduced by caregivers who have the expectation of 
deterioration following antipsychotic reduction as a possible explanation. A further paradox 
in this study is that those in the group who reduced but did not discontinue antipsychotics 
were said not to have progressed to discontinuation “if there was a significant behavioural 
worsening according to the clinician’s judgement”, suggesting that this group is, in fact, 
defined by subjective deterioration in behaviour.   
 
May et al. monitored challenging behaviour of a group of adult men with severe-profound ID 
over the course of antipsychotic withdrawal to discontinuation using frequency counts.48 
Using a very slow regime of antipsychotic taper and following individuals for at least 3 years, 
distinct groups became apparent. Five individuals (22%) showed progressive improvement in 
behaviour coinciding with antipsychotic reduction, 9 (39%) demonstrated transient 
worsening, and 9 (39%) experienced persistent behavioural worsening requiring prescription 
of either antipsychotics or other psychotropics. Those who experienced a progressive 
improvement on antipsychotic withdrawal tended to demonstrate greater baseline frequency 
of challenging behaviour. However, the study was under-powered for observed differences 
to reach statistical significance.   
 
Swanson measured total ABC score at baseline, three subsequent time-points during 
antipsychotic dose reduction, and after discontinuation.39 Total ABC score increased during 
withdrawal before falling.  
 
Branford describes the outcome of antipsychotic reduction attempts in 123 patients.44 One 
quarter achieved discontinuation without any deterioration in behaviour, 42% experienced 
deterioration in behaviour necessitating re-prescribing or attenuation of dose reduction. 
Behaviour change of the remaining individuals (33%) was not reported. 
 
Janowsky et al. report outcome at three months following antipsychotic reduction attempts 
in a group of 138 participants.45 Whilst 60% tolerated discontinuation, the remainder had a 
“significant increase in maladaptive target symptoms” which required antipsychotic re-
prescribing or dose increase. The same authors report a follow-up study of 49 of those who 
failed attempts to discontinue antipsychotic medication; 96% experienced behavioural 
relapse in future attempts to discontinue medication.46 
 
7 
 
Effect of reduction or discontinuation of antipsychotics on physical health  
 
Ten studies reported physical health outcomes resulting from antipsychotic reduction or 
discontinuation.32,35,37-39,47,49-52 Below we report physical health outcome grouped by theme.  
 
Movement effects 
 
Several studies that reported movement effects of antipsychotic reduction or discontinuation 
used the Dyskinesia Identification System: Condensed User Scale (DISCUS), a scale specifically 
developed to measure abnormal movements in individuals with ID.53 Fifteen items relating to 
movement of different body regions are rated from 0 (not present) to 4 (severe). Categorical 
definitions for clinically-relevant dyskinesia have been developed based on the total DISCUS 
score.54,55  
 
Wigal et al compared change in DISCUS score at baseline and 10-month follow-up between 
four groups defined by increase in antipsychotic dose, no change, antipsychotic dose 
reduction by <25%, and antipsychotic dose reduction ≥25% (but not matched by any other 
characteristic).37 Follow-up mean DISCUS score increased in all groups apart from the dose 
increase group, with the degree of dose reduction being positively correlated with increase 
in DISCUS score (r=0·506, p<0·001). Employing a categorical definition of dyskinesia (at least 
a ‘mild’ rating of abnormal movements in at least two body regions, or at least a ‘moderate’ 
rating of abnormal movements in one body region),55 the authors found the rate of dyskinesia 
increased from 30% at baseline to 60% at follow-up in the group who reduced medication by 
>25%, but remained stable in the groups who reduced medication by a lesser percentage or 
who underwent no dose change.  
 
A later study by the same group reports a small controlled study of 30 individuals with nested 
controls defined by antipsychotic dose changes.38 63% of those who discontinued 
antipsychotic medication developed tardive dyskinesia compared with 29% of those 
undergoing dose reduction and none of the controls or those who underwent antipsychotic 
dose increase or no change. 
 
A third study by this group reports results of antipsychotic discontinuation in 40 people and 
compare DISCUS scores with a control group at several time-points.39 The participants are 
further subdivided by anticonvulsant use, producing 4 groups in total. Mean DISCUS score 
increased after antipsychotic discontinuation in the group taking antipsychotics alone but not 
in the group who received concomitant treatment with anticonvulsant medication, raising the 
possibility of a mitigating effect of anticonvulsants in reducing discontinuation reactions.  
 
Ahmed et al found total DISCUS score was significantly increased at 6 month follow-up in the 
group who discontinued antipsychotics or underwent ≥50% dose reduction compared with 
controls (p<0·01).32 The DISCUS score in the intervention group fell between month 5 and 6, 
possibly indicating the start of a return to baseline. 
 
The concept of a ‘transient withdrawal dyskinesia’ is developed in three studies by Newell et 
al who prospectively monitored individuals undergoing planned antipsychotic dose reduction 
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to discontinuation.49-51 The authors investigated change in movement disorder over time with 
DISCUS rating and by using proxies for movement abnormalities. The first investigated lip 
movements associated with dyskinesia and demonstrated changes in quality and quantity of 
resting lip motion over the course of antipsychotic reduction and discontinuation that tended 
to revert to the pre-reduction state at follow up 6-24 months after discontinuation.49 In the 
second study, the authors again report change in DISCUS score; mean total DISCUS score 
increased from 3·4 at baseline to 10·7 at peak withdrawal (p<0·001), before falling to 
approximate baseline values at follow-up (mean follow-up DISCUS 3·5, p=NS). Rates of tardive 
dyskinesia showed a similar pattern, increasing from 31% at baseline to 85% at peak 
withdrawal, and then dropping to 38% at follow-up.51 Data presented in the third of these 
studies reports postural stability as a measure of movement disorder.50 Indices of postural 
stability and body motion changed significantly over the course of antipsychotic withdrawal 
and returned to baseline levels by follow-up. Mean total DISCUS increased from 3·5 at 
baseline (range 0-11), to 11·1 at peak withdrawal (range 3-22), and 3·8 at follow-up (range 0-
11) (p<0·01 for difference over time). This study extends the analysis by reporting a positive 
association between higher baseline levels of movement symptoms and the degree of 
withdrawal-associated dyskinesia, thereby giving some indication of people who might be 
more prone to develop problematic dyskinesia on medication reduction.  
 
 
deKuijper et al report movement side-effects as a composite of clinician-assessed 
Parkinsonism, akathisia, and extra-pyramidal side-effect ratings.47 Reporting of this outcome 
is incomplete but there was little change in average movement side-effect score between 
baseline and at the point of antipsychotic discontinuation in those who completed withdrawal 
(baseline score 2·8, follow-up 3·0, p not given).  
Autonomic function 
 
Despite disturbance of autonomic function being a known side-effect of antipsychotic drugs, 
only two studies reported the autonomic effects of their reduction or discontinuation.35,47 
deKuijper47 used the Scale Outcomes Parkinson’s disease-Autonomic symptoms (SCOPA-AUT) 
to assess autonomic adverse events at baseline and following reduction or discontinuation of 
antipsychotics.56 Both the group achieving discontinuation and the group who underwent 
dose reduction short of complete discontinuation showed significantly decreased SCOPA-AUT 
scores at 12 week follow-up (in the discontinuation group mean SCOPA-AUT changed from 
6·0 to 3·6, p<0·01; in the dose reduction group mean SCOPA-AUT changed from 6·0 to 4·9, 
p<0·01) indicating a lower burden of autonomic symptoms and a dose-response relationship. 
 
In a case report, Orfan and Kolski describe the outcome of fluphenazine withdrawal in a 74 
year old woman with ID who received the drug for behaviour control.35 The patient developed 
“severe and debilitating” rhinorrhoea following antipsychotic discontinuation. 
Weight / metabolic parameters 
 
Ahmed et al compared weight change between a group who discontinued or reduced 
antipsychotic dose by ≥50% and a control group who underwent no medication change.32 
Those in the intervention group lost an average of 2·3kg at 6 months, although this was not 
statistically different from weight change observed in controls (data not given, p>0·05).  
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deKuijper reports change in weight, BMI, and several metabolic parameters in a subgroup of 
participants who achieved antipsychotic discontinuation and remained antipsychotic free at 
12 weeks.52 Waist circumference, weight, and BMI were all significantly reduced at follow-up 
compared with baseline (waist circumference 93·2cm vs 88·8cm, p<0·001; weight 68·7kg vs 
65·2kg, p=0·02; BMI 25kg/m2 vs 23·66kg/m2, p=0·006). Systolic, but not diastolic blood 
pressure also showed a significant fall (systolic 129mmHg vs 122mmHg, p=0·02; diastolic 
80mmgHg vs 75mmHg, p=NS). Laboratory markers of the metabolic syndrome (plasma 
triglycerides, HDL, and fasting glucose) did not change significantly, although this might be a 
reflection of the relatively short duration of follow-up.  
Effect of reduction or discontinuation of antipsychotics on mental health 
 
No studies reported the effect of reduction or discontinuation of antipsychotics on the mental 
health of participants.  
Effect of reduction or discontinuation of antipsychotics on cognitive/adaptive functioning 
 
Four studies reported impact of reduction or discontinuation of antipsychotics on cognitive 
or adaptive function. In a small controlled study, Carpenter and colleagues report the effect 
on performance in a standardised computer-based cognitive test in which participants are 
required to match colours.36 All of those undergoing antipsychotic dose reduction or 
discontinuation demonstrated improved performance on the test compared with none of 
those with no medication change or not on an antipsychotic drug (number of attempts to 
reach 4 consecutive correct responses reduced by average of 29% in withdrawal group (range 
13·8-53·5%) and by 0.4% in control group (range 0·3% – 0·7%); percentage of correct 
responses increased by average of 10% in withdrawal group (range 2·7% – 19·7%) but 
declined by 1·5% in controls (range 1·3% – -4·9%); statistical tests not performed).  
 
Gedye reports the results of a small case series (n=4).34 All had demonstrated cognitive 
decline and been diagnosed clinically with dementia, at an average age of 42 years. Reduction 
and later discontinuation of antipsychotic medication resulted in substantial and sustained 
clinician-rated improvement in overall cognitive and adaptive function such that the diagnosis 
of dementia was no longer applicable.  
 
Ahmed et al32 directly observed participant behaviour for a random 1·5 hour period three 
times a month during their 6 month study and collated the amount of time participants spent 
in each of several pre-defined activities, including a measure of engagement in the activity. 
Full results are not reported but the authors state that the group who discontinued 
antipsychotics or had at least 50% dose reduction spent significantly more time engaged in 
activity than controls (p<0·05). Additional data obtained in the same study focus specifically 
on responsiveness to staff interaction.33 No difference in likelihood of response to staff 
interaction was found between the groups, probably as a high baseline response was 
recorded.  
Predictors of successful antipsychotic reduction or discontinuation 
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As part of a separate search, we identified studies that report factors associated with success 
of attempts to reduce or discontinue antipsychotic reduction (table 3). Relatively good 
evidence shows that those who have previously failed attempts to reduce antipsychotic 
medication are poor candidates for further attempts to stop medication.46 Studies tend to be 
in agreement that those on a lower baseline antipsychotic dose are more likely to have 
successful withdrawal.47,48,57,58 Other predictors of successful withdrawal attempts are less 
clear and are sometimes conflicting between studies (e.g. gender). Those with a high level of 
psychopathology (whether psychotic or not) seem to be more likely to relapse when an 
antipsychotic is withdrawn;57,59 these may be people with co-morbid mental illness which 
deteriorates when an their medication is reduced. The use of concomitant psychotropics 
(including antiepileptic drugs) has been shown to be of benefit in facilitating antipsychotic 
withdrawal attempts,59 although this is not a consistent finding.48,57 
Discussion 
 
A significant proportion of individuals in whom a concerted effort was made to reduce 
antipsychotic drugs achieved discontinuation or dose reduction. This suggests that clinicians 
can reasonably attempt to reduce antipsychotics in patients who are prescribed them for 
challenging behavioural. However, it is also the case that many of those in whom attempts 
were made to reduce or discontinue antipsychotic medication could not tolerate reduction 
and required re-prescribing. Stevenson and colleagues, writing in the aftermath of the 
restrictions imposed on the use of the first-generation agent thioridazine in 2000, contested 
that wide-scale antipsychotic withdrawal in this group is likely to cause serious harm, 
including precipitating increases in behaviour problems and mental ill-health.60  
 
Overall results from studies that report behavioural outcomes are inconclusive. Both 
deKuijper et al47 and Ahmed et al32 report no change, or even improvement in behaviour after 
antipsychotic discontinuation, although those whose behaviour deteriorated did not 
complete the withdrawal programme. Other studies report between 40% and 96% of those 
undergoing dose reduction experience significant behavioural deterioration which could 
persist for several years.44-46,48  
 
None of the included studies investigated mechanisms underlying behavioural deterioration 
following antipsychotic reduction or discontinuation. Hypotheses related to a 
pathophysiological discontinuation syndrome include; onset of super-sensitivity psychosis; 
cholinergic and/or adrenergic rebound; and emergence of movement side-effects such as 
withdrawal dyskinesia or tardive akathisia.61 In all cases, the impact of symptoms may be 
greater in people with ID due to limitations in understanding and communicating distress 
verbally, which may then find expression as challenging behaviour. Slow taper of 
antipsychotic medication has been advocated in order to minimise the risk of these 
discontinuation effects62 although the only study that compared rates of antipsychotic taper 
did not find any advantage in stopping the medication over a period of longer than 14 
weeks.47  
 
One of the most consistent findings of the review is the transient increase in dyskinesia that 
accompanied antipsychotic reduction or discontinuation associated with the use of both first- 
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and second-generation agents.63 Dyskinesia on antipsychotic reduction appears to be 
proportionate to the degree of dose reduction and may persist for several months. A return 
to baseline measures of dyskinesia was noted in studies employing longer follow-up periods, 
suggesting that it remits over time. 
 
Weight loss and some improved markers of the metabolic syndrome were noted when 
antipsychotics were reduced or discontinued.32,52 This is an important consideration in adults 
with ID who are more likely to be obese than peers of average intelligence64, and less likely 
to eat a balanced diet or achieve minimum recommended physical activity targets.65 
 
Antipsychotic medication may reduce cognitive ability in people with ID, either due to 
increased somnolence and sedation66,67 or their anti-cholinergic properties. Where change in 
cognition was investigated there was some evidence of improvement in those who reduced 
or discontinued antipsychotics. This warrants further attention given that reductions in 
cognitive capacity might negatively impact the success of psychosocial management of 
challenging behaviour and interfere with habilitation programmes.  
 
Limitations of existing research and directions for future research 
 
A major finding of the review is that current literature on the feasibility and outcome of 
antipsychotic withdrawal in people with ID is lacking in volume, quality and scope. Critical 
appraisal (table 1) revealed trials including small numbers of participants, selection bias and 
use of convenience samples, lack of control groups and of blinding, lack of standardised or 
validated outcome measures, and incomplete outcome reporting or statistical testing. The 
studies were often naturalistic and the intervention to reduce or discontinue antipsychotics 
was not well described. The length of follow-up was often short and may have been 
insufficient to capture some important outcomes. Studies may have included other 
simultaneous interventions that were not reported and could have confounded the results. 
No studies addressed the effect of reduction or discontinuation of antipsychotics on 
participant’s mental health, despite withdrawal of antipsychotics having been associated with 
new-onset psychotic symptoms even in those without previous psychosis.68 These significant 
methodological shortcomings limit the internal and external validity of the results and the 
strength of conclusions we are able to draw.  
 
[Panel 2 near here] 
Systematic review – strengths and limitations  
 
This is the first study of which we are aware that has attempted to consolidate current 
knowledge on this topic. Our search strategy was comprehensive, conducted according to a 
pre-defined protocol, and undertaken in several databases. We included all types of outcome 
measure in order to present a broad analysis.  
 
There are some limitations of our review. We chose to exclude studies published before 1990 
as we felt that the relatively rapid changes in understanding and care of people with ID  make 
it difficult to generalise results of earlier studies to current practice. Despite this date limit, a 
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number of studies that we included were conducted in large residential institutions for people 
with ID. Most studies include a high proportion of people with severe-profound ID who 
constitute only a minority of the total intellectually disabled population.  
 
Most people in included studies were taking a first-generation antipsychotic drug. This might 
limit the relevance of the review findings although there is evidence that a significant 
proportion of people taking antipsychotics still receive first-generation agents.69  
Conclusions and implications for practice 
 
Antipsychotics are likely to have a role in the multi-modal management of certain cases of 
challenging behaviour in people with ID but clinicians must respond to the prevailing attitude 
that these drugs have too often been used indiscriminately and for too long. Evidence-based 
practice guidelines and quality indicators have been developed to improve antipsychotic 
prescribing for challenging behaviour.11,70-72 These focus on the holistic assessment and 
management of challenging behaviour and the initiation of antipsychotic medication, rather 
than addressing antipsychotic discontinuation. There remains relatively little information to 
guide practice in reducing or discontinuing antipsychotics in the cohort who are already taking 
these drugs.  
 
In terms of predictors of successful or unsuccessful reduction or discontinuation of 
antipsychotics, setting and carer characteristics (as well as some individual traits) were shown 
to be important consistent with previous research.  Working conditions, staff experience, and 
attributions about challenging behaviour can influence how behaviour is reported and how it 
is managed.73-75 Where psychotropic medication is used, carers often report inadequate 
training and a desire for more information.76,77 These deficiencies in knowledge and skills can 
act as a barrier to appropriate monitoring of antipsychotics in this group, particularly as 
clinicians are often heavily reliant on third-party reports of drug effects.78 Living environment 
is similarly important in influencing prescribing; a four-fold difference in rates of antipsychotic 
prescription for behaviour has been demonstrated between those living in institutions and 
those residing in family homes, despite no underlying difference in the rates of behaviour 
disorder.79 Clearly, any attempt to transform antipsychotic prescribing to people with ID must 
recognise the wider elements that may directly influence drug use and which individual 
clinicians have little power to change.80 
 
This review exposes a gap between the available evidence and the national policy drive to 
reduce antipsychotic prescribing to people with ID. We are not able to recommend a routine 
programme of antipsychotic discontinuation in people with ID who use the drugs for 
challenging behaviour and advocate a measured response according to published 
guidelines.72 As contextual factors are important, commissioning of appropriate provider 
services and support for carers is paramount. No amount of goodwill will be sufficient to drive 
a change in the current status quo unless a systems approach to prescribing is considered.80 
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Panel 1 Summary of guidelines on the use of antipsychotic medication to manage challenging 
behaviour, adapted from NICE NG1111 
 
  
 
Consider antipsychotic medication in the management of challenging behaviour only when: 
- Psychological or other interventions alone are not effective 
- Treatment for co-morbid physical or mental disorders has been given 
- The risk to the person or others is high 
 
Only offer antipsychotic medication in combination with psychological or other interventions 
 
Antipsychotic medication should be prescribed and initially monitored by a psychiatrist who should: 
- Document the rationale for the medication 
- Prescribe the lowest dose necessary 
- Review the effectiveness and any side-effects after 3-4 weeks 
- Develop a strategy for stopping the medication  
- Stop the medication if there is no indication of response at 6 weeks 
 
Antipsychotic medication should continue to be prescribed past 6 weeks only when supported by: 
- Proven continued benefit of the drug 
- Full multidisciplinary review at 3 months and every 6 months thereafter 
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Figure 1 – study selection   
 
 
 
 
 
 
 
 
 
1018 citations identified (Medline 192; EMBASE  472; 
          PsycINFO 239; Cochran 37; CINAHL Plus 78) 
616 unique citations 
86 abstracts reviewed 
45 citations for full text review 
21 studies included 
402 duplicates removed 
532 excluded on title 
47 excluded on abstract 
24 excluded after full text review 
6 additional citations  
   identified through reference 
   checking and citation tracking 
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Study and level of 
evidence (LE) 
Participants Setting Intervention Follow-up Outcome Results Bias and 
limitations 
Carpenter et al, 
1990 
 
LE: 3 
n=10 
90% ♂ 
Mean age 30 yrs 
ID: borderline 10%, 
mild 50%, moderate 
10%, severe 30% 
 
Intervention group 
(n=7) taking 
antipsychotic for 
challenging behaviour. 
 
Control group (n=3) 
taking antipsychotic for 
behaviour or no 
antipsychotic 
medication. One 
control diagnosed with 
schizophrenia. 
State institution 
 
USA 
Reduction of 
antipsychotic medication 
by 25-100%, not 
according to a pre-
defined schedule. No 
medication changes in 
controls. 
After medication 
reduction or 
discontinuation 
Performance on a 
discrimination task 
requiring matching of 
colours presented 
sequentially on a computer 
screen; an initial colour is 
presented, followed by a 
delay, and then two colours 
– the participant must 
move a joystick in the 
direction of the matching 
colour for a correct 
response. Performance 
measured by a) trials 
needed to achieve 4 
consecutive correct 
responses and b) overall 
percentage of correct 
responses 
Intervention group improved in both 
measures of performance (trials to 4 
consecutive correct responses – mean 
improvement 28.7% reduction group vs. 
0.4% for controls; percentage of correct 
responses mean improvement 10.2% 
reduction group vs. -1.5% control group) 
(1) 
(2) 
(3) 
(4) 
(5) 
(6) 
(7) 
(8) 
Hancock et al, 
1991 
 
LE: 4 
n=42 
42% ♂  
Mean age at entry 28 
yrs 
ID: mild 5%, moderate 
5%, severe 7%, 
profound 83% 
 
5% psychiatric co-
morbidity (details not 
given) 
 
Antipsychotics: 
Thioridazine (n=36), 
chlorpromazine (n=1), 
haloperidol (n=3), 
mesoridazine (n=3) 
(one participant on 2 
drugs) 
State institution 
 
USA 
Interdisciplinary team 
programme to review 
psychotropic medication 
with a view to reduction 
or discontinuation (not 
according to a pre-
defined schedule) 
5 years 
 
 
10 years 
Number discontinuing 
antipsychotics 
 
Number discontinuing 
antipsychotics 
10/42 (24%) discontinued antipsychotics 
 
 
31/42 (74%) discontinued antipsychotics  
(8) 
(9) 
(10) 
22 
 
Orfan et al, 1993 
 
LE: 5 
n=1 
♀ 
74 yrs 
Degree of ID not given 
Antipsychotic for 
challenging behaviour 
 
Psychiatric diagnosis 
not given 
 
Antipsychotic: 
Fluphenazine 
 
Private home 
 
USA 
Single-case report 
 
Antipsychotic reduced to 
discontinuation over 3 
months 
4 year ENT symptoms Debilitating and persistent rhinorrhoea on 
fluphenazine (and benztropine) 
discontinuation 
(1) 
(4) 
(5) 
(9) 
(11) 
Lepler et al, 1993 
 
LE: 4 
n=6 on antipsychotic 
medication from larger 
cohort: 
60% ♂ 
Mean age 34 years 
ID: mild 4%, moderate 
23%, severe 46%, 
profound 31% 
 
Comorbidities not 
reported 
 
Antipsychotics: 
Trifluoperazine (n=2), 
thioridazine (n=2), 
haloperidol (n=1), 
thiothixene (n=1)  
Supported 
community 
homes 
 
USA 
Interdisciplinary team 
programme to review 
psychotropic medication 
with a view to reduction 
or discontinuation (not 
according to a pre-
defined schedule) 
4 year Number discontinuing 
antipsychotics 
 
Number on reduced dose 
of antipsychotic 
1/6 (17%) discontinued antipsychotics 
 
 
5/6 (83%) maintained on reduced dose 
(5) 
(9) 
(10) 
Spreat et al, 1993 
 
LE: 4 
n=86 
From a larger cohort 
(n=284): 
67% ♂ 
Mean age 31 yrs 
ID severe/profound 
80% 
 
Comorbidities not 
reported 
State institution 
 
USA 
Medication reduction 
trial (not according to a 
pre-defined schedule) 
1 year Change in antipsychotic use 14/86 (16%) >50% dose reduction or 
discontinuation 
26/86 (30%) dose reduction ≤50%  
46/86 (53%) same or increased dose 
(1) 
(8) 
(9) 
(10) 
23 
 
 
Antipsychotics (in 
overall group): 
Haloperidol 36%, 
mesoridazine 27%, 
thioridazine 15%, 
thioxanthene 6%, 
chlorpromazine 5%, 
trifluoperazine 4%, 
molindone 4%, 
fluphenazine 2%, 
chlorprothixene 2% 
Wigal et al, 1993 
 
LE: 3 
n=56 
64% ♂  
Mean age 33 yrs 
ID: severe-profound 
96% 
 
Comorbidities not 
reported 
 
Antipsychotics not 
reported by type 
State institution 
 
USA 
Medication review and 
dose reduction 
programme (not 
according to a pre-
defined schedule) 
 
Comparison of 4 
unmatched groups: 
Increase in antipsychotic 
dose (IN, n=5) 
No change in 
antipsychotic dose (NC, 
n=14) 
Reduction in 
antipsychotic dose of 
<25% (SD, n=21) 
Reduction in 
antipsychotic dose of 
≥25% (25D, n=16) 
10 months DISCUS score compared 
between groups 
undergoing at baseline (T1) 
and follow-up (T2) 
 
 
 
 
 
Proportion with dyskinesia 
(Schooler & Kane 
categorical definition55) 
No difference in DISCUS score between 
groups at T1. DISCUS score at T2 was 
increased in NC, SD, and 25D groups – 
greatest increase observed in 25D group. 
DISCUS score at T2 decreased in the IN 
group. Significant correlation demonstrated 
between degree of dose reduction and 
DISCUS score (r=0.506, p<0.001) 
 
Proportion with dyskinesia increased from 
30% at T1 to 60% at T2 in the 25D group, did 
not change in the SD or NC groups, and fell 
from 60% to 20% in the IN group. 
 
(1) 
(2) 
(3) 
(7) 
(8) 
(9) 
(10) 
 
Wigal et al, 1994 
 
LE: 4 
n=245 
From a larger cohort 
(n=636): 
67% ♂ 
Mean age 24 yrs 
ID: severe-profound 
96% 
 
State institution 
 
USA 
Medication review and 
dose reduction 
programme (not 
according to a pre-
defined schedule) 
 
 
1 year 
 
 
 
 
Number discontinuing 
antipsychotics 
 
 
141/245 (58%) discontinued antipsychotic 
medication 
 
 
 
(1) 
(2) 
(3) 
(7) 
(8) 
(9) 
(10) 
24 
 
Comorbidities not 
reported 
 
Antipsychotics not 
reported by type 
 n=30 
From a larger cohort 
(n=43): 
61% ♂ 
Mean age 31 yrs 
ID: severe-profound 
86% 
 
Comorbidities not 
reported 
 
Antipsychotics not 
reported by type 
 Medication review and 
dose reduction 
programme (not 
according to a pre-
defined schedule). 
Comparison of groups 
defined by antipsychotic 
discontinuation (not 
otherwise matched) 
(n=8), dose reduction 
(n=7), no change/increase 
(n=5) and control group 
not on antipsychotics 
(n=10) 
10 months Rates of dyskinesia 
(Schooler & Kane 
categorical definition55) 
5/8 (63%) in discontinuation group 
developed dyskinesia 
2/7 (29%) in dose reduction group developed 
dyskinesia 
None in the no change/increase or 
unmedicated group developed dyskinesia 
 
Jauernig et al, 
1994 
 
LE: 4 
n=25 
Demographic 
characteristics not 
reported 
 
6 with co-morbid 
mental illness (detail 
not given) 
 
Antipsychotics: 
Thioridazine (n=11) 
Chlorpromazine (n=10) 
Haloperidol (n=3) 
Fluphenazine (n=2) 
Trifluoperazine (n=1) 
(some took more than 
one antipsychotic drug) 
State institution 
 
Australia 
Medication review and 
dose reduction 
programme (not 
according to a pre-
defined schedule, but 
slow titrations preferred 
and maximum monthly 
dose decrease was 25% 
initial dose or 100mg 
chlorpromazine 
equivalents) 
2 years Number reducing or 
discontinuing antipsychotic 
medication 
 
 
Challenging behaviour 
(frequency count of target 
behaviours) 
 
3/25 (12%) discontinued antipsychotic 
medication  
19/25 (86%) underwent dose reduction 
3/25 (12%) no change in dose. 
 
Challenging behaviour frequency at follow-
up lower than baseline in all 3 (100%) whose 
antipsychotic had been discontinued and in 
15 (79%) of those who underwent dose 
reduction. 
(1) 
(3) 
(4) 
(8) 
(9) 
(10) 
(12) 
May et al, 1995 
 
LE: 4 
n=23 
100% ♂  
Mean age 42 yrs 
State institution 
 
USA 
Antipsychotic reduction 
by 10% original dose 
every 3 months to 
discontinuation. All 
3-4 years (incl. at 
least 1 year after 
discontinuation) 
Challenging behaviour 
(frequency counts) 
Three groups described on basis of change in 
challenging behaviour: transient worsening 
(n=9, 39%), progressive improvement (n=5, 
22%), persistent worsening (n=9, 39%) 
(1) 
(4) 
(7) 
(8) 
25 
 
ID: severe-profound 
100% 
 
Comorbidities not 
reported 
 
Thioridazine used in all 
participants 
completed 
discontinuation. 
 
Those in the progressive improvement group 
tended to receive lower initial doses of 
antipsychotic and have higher baseline levels 
of challenging behaviour (differences 
between groups not statistically significant, 
data not given).  
(9) 
(11) 
Branford, 1996 
 
LE: 4 
n=123 
From a larger cohort 
(n=198): 
66% ♂ 
Mean age 43 yrs 
ID: borderline 1%, mild 
13%, moderate 30%, 
severe 56% 
 
Psychiatric comorbidity: 
Schizophrenia 4%, 
affective disorder 7%, 
anxiety disorder 16%, 
personality disorder 8% 
 
Antipsychotics: 
Thioridazine (n=98), 
chlorpromazine (n=52), 
zuclopenthixol (n=34), 
haloperidol (n=15),  
other (n=15) (some 
took more than one 
antipsychotic drug) 
47% hospital, 
53% community 
 
UK 
Medication review and 
dose reduction 
programme (not 
according to a pre-
defined schedule, most 
dose reduction was over 
a 3 month period) 
12 months Number reducing or 
discontinuing antipsychotic 
medication 
 
 
Challenging behaviour 
(anecdotal report)  
31/123 (25%) discontinued antipsychotic 
56/123 (46%) reduced dose 
27/123 (22%) same dose 
9/123 (7%) higher dose 
 
31/123 (25%) no deterioration  
52/123 (42%) deterioration in behaviour 
40/123 (33%) not reported 
(1) 
(4) 
(9) 
(10) 
(13) 
Swanson et al, 
1996 
 
LE: 3 
n=80 
61% ♂ 
Mean age 38 yrs 
ID: moderate 1%, 
severe 16%, profound 
80%, unknown 3% 
 
1% diagnosed mental 
illness 
State institution 
 
USA 
Medication review and 
dose reduction 
programme to 
discontinuation (not 
according to a pre-
defined schedule) 
 
Four groups compared 
(unmatched) 
3 monthly 
intervals to 6 
months after 
antipsychotic 
discontinuation 
 
Dyskinesia (DISCUS score) 
 
 
 
 
 
 
 
 
Transient increase in average DISCUS score in 
antipsychotic-only group after withdrawal 
with return to baseline 6 months after 
discontinuation. No consistent change in 
those withdrawn from antipsychotics who 
were also taking anti-convulsants. No change 
in control groups (no medication and anti-
convulsant medication only) 
 
(1) 
(2) 
(3) 
(7) 
(8) 
(10) 
 
26 
 
 
Antipsychotics: 
Thioridazine (n=18), 
haloperidol (n=7), 
loxapine (n=6) 
chlorpromazine (n=5), 
other (n=4) 
Intervention groups: 
antipsychotics only 
(n=19), antipsychotics + 
anti-convulsants (n=21) 
Control groups: no 
medication (n=19), anti-
convulsants only (n=21) 
Challenging behaviour 
(ABC) 
 
 
 
No consistent change in antipsychotic only 
group over course of withdrawal. Transient 
increase in average ABC during antipsychotic 
withdrawal in those also prescribed anti-
convulsants. No change in control groups. 
Gedye, 1998 
 
LE: 4 
n=4 
75% ♂ 
Mean age 42 yrs 
Degree of ID not given 
 
Comorbidities not 
reported 
 
Antipsychotics: 
Thioridazine (n=1), 
haloperidol (n=1), 
pimozide (n=1), 
loxapine (n=1) 
Not known 
 
USA 
Case series 
 
Antipsychotic 
discontinuation (not 
according to a pre-
defined schedule) 
Not specified Clinical assessment  Antipsychotic discontinuation associated 
with improvement in cognitive function and 
revocation of previous diagnosis of dementia 
in all cases 
(1) 
(3) 
(4) 
(5) 
(9) 
(11) 
Ahmed et al, 2000 
 
LE: 2 
n=56 
48% ♂ 
Mean age 43 yrs 
ID: mild 7%, moderate 
30%, severe 26%, 
profound 35% 
 
Comorbidities not 
reported but none had 
psychosis 
 
Antipsychotics: 
Thioridazine (n=18), 
haloperidol (n=13), 
chlorpromazine (n=8), 
other (n=17) 
 
 
45% hospital 
55% community 
 
UK 
RCT – participants 
randomly assigned to 
intervention or control 
groups. 
 
Intervention group 
(n=36): reduction of 
antipsychotic by 25% 
monthly to 
discontinuation  
 
Control group (n=20): no 
medication changes 
6 months (1 
month after 
planned 
discontinuation)  
Number reducing or 
discontinuing antipsychotic 
medication (intervention 
group) 
 
Challenging behaviour 
(ABC)  
 
Observed behaviour 
 
 
 
DISCUS 
 
 
 
Weight  
12/36 (33%) discontinued medication 
7/36 (19%) ≥50% reduction in dose 
17/36 (48%) unable to tolerate reduction 
 
 
No difference between group who 
discontinued or achieved ≥50% reduction 
and controls 
 
Higher engagement activity in 
discontinuation/reduction group compared 
with controls (p<0.05). No difference in 
maladaptive behaviour among groups 
 
DISCUS score increased in group who 
discontinued or achieved ≥50% dose 
reduction compared with controls (p<0.01) 
 
Average weight loss of 2.3kg in group who 
discontinued or achieved ≥50% dose 
(1) 
(2) 
(3) 
(7) 
(13) 
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reduction but no statistically significant 
difference from controls 
Newell et al, 2000 
 
LE: 4 
n=6 
67% ♂ 
Mean age 37 yrs 
ID: moderate 50%, 
severe 33%, profound 
17% 
 
No comorbidities 
 
Antipsychotics: 
haloperidol (n=3) 
thioridazine (n=2) 
Mesoridazine (n=1) 
State institution 
 
USA 
Antipsychotic dose 
reduction by approx. 25% 
every 3 mths to 
discontinuation 
Post-
discontinuation 
follow-up of 
6months-2years 
Video analysis of lip 
movement (as proxy of TD) 
 
 
 
DISCUS score 
Dyskinetic movements increased during 
antipsychotic withdrawal followed by a 
reduction post-discontinuation, although not 
to baseline levels 
 
Results not given 
(1) 
(3) 
(4) 
(5) 
(7) 
(8) 
(9) 
(12) 
(13) 
Newell et al, 2001 
 
LE: 4 
n=26 
69%  ♂ 
Mean age 35 yrs 
ID: mild 4%, moderate 
20%, severe 46%, 
profound 31% 
 
No psychiatric 
comorbidities 
 
Antipsychotics: 
haloperidol (n=9) 
thioridazine (n=9) 
chlorpromazine (n=3) 
mosoridazine (n=3) 
loxapine (n=1) 
trifluperazine (n=1) 
State institution 
 
USA 
Antipsychotic dose 
reduction by approx.. 
25% every 2-4 mths to 
discontinuation 
Post-
discontinuation 
follow-up of 12 
months 
DISCUS score 
 
 
 
 
 
Tardive dyskinesia 
(Kalachnik & Sprague 
categorical definition) 
Mean total DISCUS increased significantly 
from baseline during antipsychotic 
withdrawal (3.423 to 10.731, p<0.001), 
before returning to baseline levels at follow-
up (3.462). 
 
Prevalence in group increased from 31% at 
baseline to 85% during antipsychotic 
withdrawal, and fell to 38% at follow-up 
(1) 
(3) 
(8) 
(12) 
Newell et al, 2002 
 
LE: 4 
n=20 
75% ♂ 
Mean age 37 yrs 
ID: severe-profound 
100% 
 
No comorbidities 
 
State institution 
 
USA 
Antipsychotic dose 
reduction by approx.. 
25% every 3 mths to 
discontinuation 
 
Post-
discontinuation 
follow-up of 12 
months 
Postural stability 
 
 
 
 
DISCUS 
Indices of postural stability changed 
significantly over the course of medication 
withdrawal and tended to return to baseline 
levels at follow-up  
 
Mean total DISCUS increased significantly 
from baseline during antipsychotic 
withdrawal (3.52 to 11.10, p<0.01), before 
(1) 
(3) 
(4) 
(7) 
(8) 
(9) 
(12) 
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Antipsychotics: 
thioridazline (n=7) 
haloperidol (n=5) 
trifluoperazine (n=3) 
loxapine (n=3) 
chlorpromazine (n=2) 
returning to baseline levels at follow-up 
(3.75).  
Smith et al, 2002 
 
LE: 2 
 
Additional 
reporting of 
Ahmed et al, 2000 
 
n=56 
48% ♂ 
Mean age 43 yrs 
ID: mild 7%, moderate 
30%, severe 26%, 
profound 35% 
 
Comorbidities not 
reported but none had 
psychosis 
 
Antipsychotics: 
Thioridazine (n=18), 
haloperidol (n=13), 
chlorpromazine (n=8), 
other (n=17) 
 
45% hospital 
55% community 
 
UK 
RCT 
 
Intervention group 
(n=36): reduction of 
antipsychotic by 25% 
monthly to 
discontinuation  
 
Control group (n=20): no 
medication changes 
6 months (1 
month after 
planned 
discontinuation) 
Responsiveness to staff 
interaction 
No difference between group undergoing 
antipsychotic reduction/discontinuation and 
control group 
(1) 
(2) 
(3) 
(7) 
Janowsky et al, 
2006 
 
LE: 4 
n=138  
from a larger cohort 
(n=151): 
60% ♂ 
Mean age 48 yrs 
ID: severe-profound 
100% 
 
Psychiatric 
comorbidities incl. 
bipolar disorder, 
autism, stereotyped 
movements with self-
injury, intermittent 
explosive disorder, 
mood disorder, 
obsessive-compulsive 
State institution 
 
USA 
Medication review and 
dose reduction 
programme (not 
according to a pre-
defined schedule) 
 
3 months 
 
 
 
 
Ave 10 years 
Number discontinuing 
antipsychotic medication 
 
 
 
Number discontinuing 
antipsychotic medication 
 
83/138 (60%) discontinued antipsychotic 
medication 
55/138 (40%) experienced behavioural 
disturbance requiring re-prescribing  
 
74/138 (54%) discontinued antipsychotic 
medication 
64/138 (46%) could not discontinue 
antipsychotic medication 
(1) 
(8) 
(9) 
(10) 
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disorder, psychotic 
disorder, anxiety 
disorder, behaviour 
disorder, oppositional 
defiant disorder 
(percentages not given) 
but antipsychotics given 
to manage behaviour 
 
Antipsychotics not 
given by type 
Janowsky et al, 
2008 
 
LE: 
 
n=49 
from a larger cohort 
(n=57): 
65% ♂ 
Mean age 52 yrs 
ID: severe-profound 
100% 
 
All had experienced 
behavioural worsening 
on a previous attempt 
to reduce or 
discontinue 
antipsychotics  
 
Psychiatric 
comorbidities incl. 
bipolar disorder, 
autism, stereotyped 
movements with self-
injury, intermittent 
explosive disorder, 
mood disorder, 
obsessive-compulsive 
disorder, psychotic 
disorder, anxiety 
disorder, behaviour 
disorder, oppositional 
defiant disorder 
State institution 
 
USA 
Medication review and 
dose reduction 
programme (not 
according to a pre-
defined schedule but 
most were reduced at 
≤10% per month) 
 
Up to 15 years 
(average follow-
up not given) 
Number discontinuing 
antipsychotic medication 
 
 
 
Challenging behaviour 
(anecdotal report) 
4/49 (8%) discontinued antipsychotic 
medication 
45/49 (92%) could not discontinue 
antipsychotic medication  
 
2/49 (4%) no deterioration in maladaptive 
behaviour 
47/49 (96%) experienced relapse in 
maladaptive behaviour on antipsychotic 
reduction  
(1) 
(8) 
(9) 
(10) 
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(percentages not given) 
but antipsychotics given 
to manage behaviour 
 
Antipsychotics (larger 
group): 
haloperidol (n=24), 
thioridazine (n=20), 
chlorpromazine (n=7), 
thiothixine (n=5), 
loxapine (n=1) 
deKuijper et al, 
2013 
 
LE: 4 
 
Additional 
reporting of 
deKuijper et al, 
2014 
 
n=36 
from a larger cohort 
(n=98): 
64% ♂ 
Mean age 50 yrs 
ID: mild 7%, moderate 
30%, severe 26%, 
profound 35% 
 
54% had co-morbid 
mental illness (autism 
spectrum condition 
45%, ADHD 3%, mood 
disorder 4%, other 4%, 
none had schizophrenia 
or bipolar disorder) 
 
Antipsychotics: 
Pipamperone (n=64), 
haloperidol (n=18), 
levomepromazine 
(n=7), 
pimozide (n=1), 
risperidone (n=15), 
olanzapine (n=8) (some 
took more than one 
antipsychotic drug) 
 
Residential care 
centres (74%) 
and community 
settings (26%) 
 
Netherlands 
Planned reduction of 
antipsychotic by 12.5% 
every 2 or 4 weeks 
(random allocation to 
reduction schedule in 1:1 
ratio) 
 
Results of those achieving 
antipsychotic 
discontinuation (n=36) 
26 or 40 weeks 
(12 weeks after 
discontinuation, 
depending on 
reduction 
schedule (n=21 on 
faster reduction 
schedule, n=15 on 
slower reduction 
schedule) 
Waist circumference 
Weight 
BMI 
Systolic BP 
Diastolic BP 
Plasma triglycerides 
Plasma HDL 
Plasma glucose 
Mean change -4.4cm (p<0.001) 
Mean change -3.5kg (p=0.02) 
Mean change -1.41kg/m2 (p=0.006) 
Mean change -7.1mmHg (p=0.02) 
Mean change -4.3mmHg (p=NS) 
Mean change +0.05mmol/L (p=NS) 
Mean change +0.04mmol/L (p=NS) 
Mean change -0.09mmol/L (p=NS) 
(1) 
(3) 
(7) 
(8) 
(12) 
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deKuijper et al, 
2014 
 
LE: 4 
n=98 
64% ♂ 
Mean age 50 yrs 
ID: mild 7%, moderate 
30%, severe 26%, 
profound 35% 
 
54% had co-morbid 
mental illness (autism 
spectrum condition 
45%, ADHD 3%, mood 
disorder 4%, other 4%, 
none had schizophrenia 
or bipolar disorder) 
 
Antipsychotics: 
Pipamperone (n=64), 
haloperidol (n=18), 
levomepromazine 
(n=7), 
pimozide (n=1), 
risperidone (n=15), 
olanzapine (n=8) (some 
took more than one 
antipsychotic drug) 
 
 
 
 
 
Residential care 
centres (74%) 
and community 
settings (26%) 
 
Netherlands 
 
Reduction of 
antipsychotic by 12.5% 
every 2 or 4 weeks 
(random allocation to 
reduction schedule in 1:1 
ratio) but under clinician 
control  
Planned 
discontinuation: 
14 or 28 weeks 
after initiation of 
dose reduction, 
depending on 
reduction 
schedule  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number reducing or 
discontinuing antipsychotic 
medication 
 
 
 
ABC  
 
 
 
VAS 
 
 
 
CGI-I 
 
 
 
SCOPA-AUT (autonomic 
symptoms) 
 
EPS (composite of scores on 
akathisia scale, 
parkinsonism scale and 
AIMS) 
 
43/98 (44%) discontinued antipsychotics. 
55/98 (56%) could not discontinue 
medication but achieved average dose 
reduction of 41-48% compared with 
baseline. 
 
Significant improvement from baseline in 
group who achieved discontinuation (47 to 
32, p<0.01).  
 
No change from baseline in group who 
discontinued antipsychotics (mean 6.4 to 6.5, 
p=0.76) 
 
14% improved, 83% no change, 2% worse 
compared with baseline in group 
discontinuing antipsychotics  
 
Significant decrease in those achieving 
discontinuation (mean 6.0 to 3.0, p<0.01). 
 
No change in those who achieved 
antipsychotic discontinuation (mean 2.8 to 
2.8, statistical test not reported) 
 
(1) 
(3) 
(7) 
(8) 
(12) 
    Follow-up: 26 or 
40 weeks, 
depending on 
reduction 
schedule (i.e. 12 
weeks after 
planned 
discontinuation) 
 
Number reducing or 
discontinuing antipsychotic 
medication 
 
 
 
ABC  
 
 
 
36/98 (37%) remained off antipsychotics. 
62/98 (56%) who did not discontinue or who 
were re-prescribed medication after 
discontinuation received average doses 15-
20% lower that baseline. 
 
Significant improvement from baseline in 
group who achieved discontinuation (mean 
47 to 37, p=0.03).  
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VAS 
 
 
 
CGI-I 
 
 
 
SCOPA-AUT (autonomic 
symptoms) 
 
EPS (composite of scores on 
akathisia scale, 
parkinsonism scale and 
AIMS) 
No change from baseline in group who 
discontinued antipsychotics (mean 6.4 to 6.5, 
p=0.76) 
 
31% improved, 64% no change, 5% worse 
compared with baseline in group 
discontinuing antipsychotics  
 
Significant decrease in those who achieved 
discontinuation (mean 6.0 to 3.6, p=0.01). 
 
Slight increase in those who achieved 
antipsychotic discontinuation (mean 2.8 to 
3.0, statistical test not reported). 
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ABC, aberrant behaviour checklist; AIMS, abnormal involuntary movement scale; BMI, body mass index; BP, blood pressure; DISCUS, dyskinesia identification system: condensed user scale; 
CGI-I, clinical global impression-improvement scale; ENT, ear, nose and throat; EPS, extrapyramidal symptoms; HDL, high density lipoprotein; ID, intellectual disability; RCT, randomised 
controlled trial; SCOPA-AUT, scale outcomes Parkinson’s disease – automonic symptoms; TD, tardive dyskinesia; VAS, visual analogue scale 
Table 1 Summary of included studies 
 
Key to biases and limitations (in order of appearance in table): 
 
(1) Selection bias 
(2) Control group inadequately matched 
(3) Lack of blinding 
(4) Use of unvalidated measures/non-standard assessment tools 
(5) Small sample size (<10 undergoing intervention) 
(6) Possible practise effect 
(7) Statistics or statistical tests inadequately reported or inappropriate  
(8) Institutional setting 
(9) Missing baseline information 
(10) Intervention poorly defined 
(11) Retrospective report/possible recall bias 
(12) Lack of control group 
(13) Selective reporting/incomplete outcome data
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Study n Follow-up Antipsychotic 
discontinued at 
follow-up 
Antipsychotic 
discontinued 
or reduced at 
follow-up 
Antipsychotic 
reduced at 
follow-up 
Antipsychotic 
reduced or no 
change at 
follow-up 
Antipsychotic 
no change or 
increased at 
follow-up 
Hancock40 42 5 yrs 10/42 (24%) - - 32/42 (76%) - 
  10 yrs 31/42 (74%) - - 11/42 (26%) - 
Lepler41 6 4 yrs 1/6 (17%) - 5/6 (83%) - - 
Spreat42 86 1 yr - 40 (47%) - 46/86 (53%) - 
Wigal38 245 1 yr 141/245 (58%) - - 104/245 (42%) - 
Jauernig43 25 2 yrs 3/25 (12%) - 19/25 (76%) - 3/25 (12%) 
Branford44 123 1 yr 31/123 (25%) - 56/123 (46%) - 36/123 (29%) 
Ahmed32 56 6 mths 12/36 (33%) - 7/36 (19%) - 17/36 (47%) 
Janowsky45 138 3 mths 83/138 (60%) - - 55/138 (40%) - 
  10 yrs 74/138 (54%) - - 64/138 (46%) - 
Janowsky46 49 Up to 15 yrs 2/49 (4%)   47/49 (96%)  
deKuijper47 51 26 wks 21/51 (41%) - - 30/51 (59%) - 
 47 40 wks 15/47 (32%) - - 32/47 (68%) - 
 
Table 2 – Outcome of interventions to reduce or discontinue antipsychotic medication 
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Demographic factors 
Male sex47 
Female sex40 
Clinical factors 
Higher baseline antipsychotic dose47,48,57,58 
Higher baseline behavioural symptoms47,48,57 
Lower baseline behavioural symptoms48 
Higher baseline extrapyramidal symptoms47 
Higher baseline psychopathology57,59 
Previous unsuccessful antipsychotic withdrawal attempt46 
Absence of co-administration of other psychoactive medication39, 59 
Setting/environmental factors 
More restrictive environments32 
Lower staffing levels and training32 
 
Table 3 Factors shown to be associated with unsuccessful attempts to reduce or discontinue 
antipsychotic medication in people with ID taking antipsychotics for challenging behaviour 
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Panel 2 Future research directions 
 
 
  
 High quality studies that investigate the feasibility of reduction or discontinuation 
of antipsychotics used for challenging behaviour in people with intellectual 
disability are needed.  
 Baseline characteristics of study participants should be well-defined and include 
screening for co-morbid mental illness using standardised instruments (such as the 
PAS-ADD) or adapted diagnostic criterial (such as the DC-LD).  
 To be useful in guiding management decisions, studies should be adequately 
powered to elucidate environmental and individual characteristics that are 
associated with successful and unsuccessful attempts to reduce or discontinue 
antipsychotic medication.  
 Although patient and caregiver attitude towards antipsychotic medication for 
challenging behaviour and concordance with treatment plans quite clearly 
influence their success, these were not mentioned in included studies, and should 
be investigated further.  
 The economic impact and change in resource use resulting from antipsychotic 
reduction or discontinuation for challenging behaviour is likely to be complex and 
will require the balancing of short-term risks (e.g. management of behavioural 
deterioration) against potential longer-term savings (e.g. in prescription costs and 
managing long-term adverse side-effects). 
 Novel or pragmatic study designs, possibly using routinely-collected health data, 
might be appropriate for further investigating this topic.   
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Appendix A – full list of search terms 
 
Medline search terms (conducted on 27/03/2016) 
 
Terms for intellectual 
disability (title or abstract) 
Terms for anti-psychotic (title 
or abstract) 
Terms for reduction or 
discontinuation (title or abstract) 
Intellectual* disab* Anti$psychotic* Withdraw* 
Intellectual* impair* Neuroleptic* Discontinu* 
Intellectual* retard* Major tranquil*i*er* Stop* 
Intellectual* handicap* Dopamine antagonist Remov* 
Intellectual* subnormal* Phenothiazine* Reduc* 
Intellectual* deficien* Butyrophenone* Minimi* 
Learning disab* Thioxanthene* Cessation 
Learning impair* Diphenylbutylpiperidine* Taper* 
Learning retard* Benperidol  
Learning handicap* Chlorpromazine  
Learning subnormal* Droperidol  
Learning deficien* Flupent*ixol  
Mental* disab* Haloperidol  
Mental* impair* Levomepromazine  
Mental* retard* Peric*azine  
Mental* handicap* Perphenazine  
Mental* subnormal* Pimozide  
Mental* deficien* Prochlorperazine  
Developmental* disab* Promazine  
Developmental* impair* Sulpiride  
Developmental* retard* Trifluoperazine  
Developmental* handicap* Zuclopent*ixol  
Developmental* 
subnormal* 
Amisulp*ride  
Developmental* deficien* Aripiprazole  
Neurodevelopmental* 
disab*  
Asenapine  
Neurodevelopmental* 
impair* 
Clozapine  
Neurodevelopmental* 
retard* 
Lurasidone  
Neurodevelopmental* 
handicap* 
Olanzapine  
Neurodevelopmental* 
subnormal* 
Paliperidone  
Neurodevelopmental* 
deficien* 
Quetiapine  
 Risperidone  
 Thioridazine  
MeSH headings 
Intellectual Disability Antipsychotic Agents Substance Withdrawal Syndrome  
Mentally Disabled Persons Dopamine Antagonists  
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PsycINFO search terms (conducted on 27/03/2016) 
 
Terms for intellectual 
disability (title or abstract) 
Terms for anti-psychotic (title 
or abstract) 
Terms for reduction or 
discontinuation (title or abstract) 
Intellectual* disab* Anti-psychotic* Withdraw* 
Intellectual* impair* Antipsychotic* Discontinu* 
Intellectual* retard* Neuroleptic* Stop* 
Intellectual* handicap* Major tranquil*i*er* Remov* 
Intellectual* subnormal* Dopamine antagonist Reduc* 
Intellectual* deficien* Phenothiazine* Minimi* 
Learning disab* Butyrophenone* Cessation  
Learning impair* Thioxanthene* Taper*  
Learning retard* Diphenylbutylpiperidine*  
Learning handicap* Benperidol  
Learning subnormal* Chlorpromazine  
Learning deficien* Droperidol  
Mental* disab* Flupent*ixol  
Mental* impair* Haloperidol  
Mental* retard* Levomepromazine  
Mental* handicap* Peric*azine  
Mental* subnormal* Perphenazine  
Mental* deficien* Pimozide  
Developmental* disab* Prochlorperazine  
Developmental* impair* Promazine  
Developmental* retard* Sulpiride  
Developmental* handicap* Trifluoperazine  
Developmental* 
subnormal* 
Zuclopent*ixol  
Developmental* deficien* Amisulp*ride  
Neurodevelopmental* 
disab*  
Aripiprazole  
Neurodevelopmental* 
impair* 
Asenapine  
Neurodevelopmental* 
retard* 
Clozapine  
Neurodevelopmental* 
handicap* 
Lurasidone  
Neurodevelopmental* 
subnormal* 
Olanzapine  
Neurodevelopmental* 
deficien* 
Paliperidone  
 Quetiapine  
 Risperidone  
 Thioridazine  
MeSH headings 
Intellectual development 
disorder 
Neuroleptic drugs Drug withdrawal  
Developmental disabilities Dopamine antagonists   
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EMBASE search terms (conducted on 28/03/2016) 
 
Terms for intellectual 
disability (title or abstract) 
Terms for anti-psychotic (title 
or abstract) 
Terms for reduction or 
discontinuation (title or abstract) 
Intellectual* disab* Anti-psychotic* Withdraw* 
Intellectual* impair* Antipsychotic* Discontinu* 
Intellectual* retard* Neuroleptic* Stop* 
Intellectual* handicap* Major tranquil*i*er* Remov* 
Intellectual* subnormal* Dopamine antagonist Reduc* 
Intellectual* deficien* Phenothiazine* Minimi* 
Learning disab* Butyrophenone* Cessation 
Learning impair* Thioxanthene* Taper* 
Learning retard* Diphenylbutylpiperidine*  
Learning handicap* Benperidol  
Learning subnormal* Chlorpromazine  
Learning deficien* Droperidol  
Mental* disab* Flupent*ixol  
Mental* impair* Haloperidol  
Mental* retard* Levomepromazine  
Mental* handicap* Peric*azine  
Mental* subnormal* Perphenazine  
Mental* deficien* Pimozide  
Developmental* disab* Prochlorperazine  
Developmental* impair* Promazine  
Developmental* retard* Sulpiride  
Developmental* handicap* Trifluoperazine  
Developmental* 
subnormal* 
Zuclopent*ixol  
Developmental* deficien* Amisulp*ride  
Neurodevelopmental* 
disab*  
Aripiprazole  
Neurodevelopmental* 
impair* 
Asenapine  
Neurodevelopmental* 
retard* 
Clozapine  
Neurodevelopmental* 
handicap* 
Lurasidone  
Neurodevelopmental* 
subnormal* 
Olanzapine  
Neurodevelopmental* 
deficien* 
Paliperidone  
 Quetiapine  
 Risperidone  
 Thioridazine  
MeSH headings 
intellectual impairment  neuroleptic agent drug withdrawal 
mental deficiency dopamine receptor blocking 
agent 
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CINAHL Plus search terms (conducted on 28/03/2016) 
 
Terms for intellectual 
disability 
Terms for anti-psychotic Terms for reduction or 
discontinuation 
Intellectual* disab* Anti-psychotic* Withdraw* 
Intellectual* impair* Antipsychotic* Discontinu* 
Intellectual* retard* Neuroleptic* Stop* 
Intellectual* handicap* Major tranquiliser* Remov* 
Intellectual* subnormal* Major tranquilliser* Reduc* 
Intellectual* deficien* Major tranquilizer* Cessation  
Learning disab* Major tranqillizer* Taper*  
Learning impair* Dopamine antagonist*  
Learning retard* Phenothiazine*  
Learning handicap* Butyrophenone*  
Learning subnormal* Thioxanthene*  
Learning deficien* Diphenylbutylpiperidine*  
Mental* disab* Benperidol  
Mental* impair* Chlorpromazine  
Mental* retard* Droperidol  
Mental* handicap* Flupenthixol  
Mental* subnormal* Flupentixol  
Mental* deficien* Haloperidol  
Developmental* disab* Levomepromazine  
Developmental* impair* Periciazine  
Developmental* retard* Pericyazine  
Developmental* handicap* Perphenazine  
Developmental* 
subnormal* 
Pimozide  
Developmental* deficien* Prochlorperazine  
Neurodevelopmental* 
disab*  
Promazine  
Neurodevelopmental* 
impair* 
Sulpiride  
Neurodevelopmental* 
retard* 
Trifluoperazine  
Neurodevelopmental* 
handicap* 
Zuclopenthixol  
Neurodevelopmental* 
subnormal* 
Zuclopentixol  
Neurodevelopmental* 
deficien* 
Amisulpride  
 Amisulpiride  
 Aripiprazole  
 Asenapine  
 Clozapine  
 Lurasidone  
 Olanzapine  
 Paliperidone  
 Quetiapine  
 Risperidone  
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 Thioridazine  
CINAHL headings 
Intellectual disability Dopamine antagonists Substance withdrawal syndrome 
Mentally disabled persons  Antipsychotic agents Substance withdrawal, 
controlled 
 Antipsychotic agents, 
phenothiazine 
 
 Antipsychotic agents, 
butyrophenone 
 
 
 
Systematic review – Cochrane (conducted on 28/03/16) 
 
Terms for intellectual 
disability 
Terms for anti-psychotic Terms for reduction or 
discontinuation 
(Intellectual* OR learning* 
OR mental* OR 
developmental* OR 
neurodevelopmental*) 
NEXT (disab* OR impair* OR 
retard* OR handicap* OR 
subnormal* OR deficien*) 
Anti-psychotic* Withdraw* 
 Neuroleptic* Discontinu* 
 “major tranquiliser”  Stop* 
 “Dopamine antagonist” Remov* 
  Reduc* 
  Minimi* 
  Cessation 
  Taper*  
MeSH terms 
Intellectual disability Dopamine antagonists Substance withdrawal syndrome  
Mentally disabled persons  Antipsychotic agents  
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Appendix B – studies excluded after full-text review 
 
Studies with no individual outcomes reported, including those reporting average changes in 
medication use only 
Findholt and Emmett81 
Luchins et al59 
Bisconer et al82 
Branford57 
Howerton et al83 
Ruggerini et al84 
Lim85 
Observational studies with no active intervention to reduce or discontinue antipsychotic drugs 
Wressell et al86 
Etherington et al87 
Gravestock88 
Branford89 
Studies reporting no new suitable information 
Branford90 
Studies where most or all participants were taking antipsychotic for mental illness 
Pary et al91 
Sovner92 
Davies et al93 
Margetić and Aukst- Margetić94 
Stonecipler et al95 
Janowsky et al96 
Studies describing switch of antipsychotics 
Matthews and Weston58 
Stevenson et al60 
Studies evaluating efficacy of antipsychotics in managing challenging behaviour  
Haessler et al97 
Haßler et al98 
Studies including children/adolescents only 
Rapp et al99 
Review articles/expert opinion 
Levitas et al100 
 
  
43 
 
Appendix C – Behavioural outcome measures used in included studies 
 
Method/instrument Description 
Aberrant behaviour 
checklist (ABC) 
58 item carer-rated scale measuring range of behavioural disturbances in 5 sub-
scales. Sensitive to changes in behaviour secondary to medication change 
Visual analogue scale 
(VAS) 
Target behaviour(s) rated by caregiver between 0 (severe) and 10 (mild) on a 
generic scale used to quantify subjective experience 
Direct observation  Formal categorisation of behaviour according to pre-defined groups in discrete 
time periods during which the behaviour of the participant is observed 
Descriptive report Any statement(s) where any aspect of the behaviour of individuals or of the 
group is described  
 
 
 
